Pharmaceutical

(Nanatinostat + valganciclovir) by Viracta Therapeutics for Solid Tumor: Likelihood of Approval

(Nanatinostat + valganciclovir) is under clinical development by Viracta Therapeutics and currently in Phase II for Solid Tumor.

Dec 24, 2023 - 18:00
(Nanatinostat + valganciclovir) is under clinical development by Viracta Therapeutics and currently in Phase II for Solid Tumor.
Read the original article

Tags:

Previous Article

Devimistat by Cornerstone Pharmaceuticals for Soft Tissue Sarcoma: Likelihood of...

Next Article

Electronic “soil” enhances crop growth

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharma budget tightening trickles down to Doximity

STAT+: Pharma budget tightening trickles down to Doximity

Aug 13, 2023

STAT+: Hospitals struggle to make money on CAR-T cancer therapies, but their fortunes may change

STAT+: Hospitals struggle to make money on CAR-T cancer...

Jul 20, 2023

Medical devices with screens aren’t accessible to the blind. Congress has chance to change that

Medical devices with screens aren’t accessible to the b...

Feb 5, 2024